MX392103B - Compuestos para el tratamiento de la t-pll. - Google Patents
Compuestos para el tratamiento de la t-pll.Info
- Publication number
- MX392103B MX392103B MX2019015208A MX2019015208A MX392103B MX 392103 B MX392103 B MX 392103B MX 2019015208 A MX2019015208 A MX 2019015208A MX 2019015208 A MX2019015208 A MX 2019015208A MX 392103 B MX392103 B MX 392103B
- Authority
- MX
- Mexico
- Prior art keywords
- pll
- treatment
- compounds
- plltherapy
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709402.0A GB201709402D0 (en) | 2017-06-13 | 2017-06-13 | Compounds for treating t-pll |
| PCT/EP2018/065664 WO2018229132A1 (en) | 2017-06-13 | 2018-06-13 | Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019015208A MX2019015208A (es) | 2022-05-03 |
| MX392103B true MX392103B (es) | 2025-03-21 |
Family
ID=59358363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015208A MX392103B (es) | 2017-06-13 | 2018-06-13 | Compuestos para el tratamiento de la t-pll. |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11318117B2 (https=) |
| EP (1) | EP3638231B1 (https=) |
| JP (1) | JP7195283B2 (https=) |
| KR (1) | KR102655833B1 (https=) |
| AR (1) | AR112101A1 (https=) |
| AU (1) | AU2018285821B2 (https=) |
| BR (1) | BR112019026484A2 (https=) |
| CA (1) | CA3067276A1 (https=) |
| ES (1) | ES2966954T3 (https=) |
| GB (1) | GB201709402D0 (https=) |
| IL (1) | IL271017A (https=) |
| MX (1) | MX392103B (https=) |
| TW (1) | TW201919616A (https=) |
| WO (1) | WO2018229132A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| KR20210105380A (ko) * | 2018-12-18 | 2021-08-26 | 먼디파머 인터내셔널 코포레이션 리미티드 | 다발성 골수종을 치료하기 위한 화합물 |
| US12186393B2 (en) | 2019-08-02 | 2025-01-07 | Onehealthcompany, Inc. | Method of treating transitional cell carcinoma in a canine by administering lapatinib, wherein the carcinoma harbors a BRAF mutation |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5882941A (en) | 1994-05-04 | 1999-03-16 | Massachusette Institute Of Technology | Programmable genotoxic agents and uses therefor |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6133248A (en) | 1997-06-13 | 2000-10-17 | Cydex, Inc. | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6214852B1 (en) | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| AU2001273413A1 (en) | 2000-07-12 | 2002-01-21 | Immunex Corporation | Method for treating cancer using an interleukin- 4 antagonist |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1335898B1 (en) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
| CN1764648A (zh) | 2003-01-13 | 2006-04-26 | 安斯泰来制药有限公司 | 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物 |
| JP4790594B2 (ja) | 2003-02-25 | 2011-10-12 | トポターゲット ユーケー リミテッド | Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物 |
| JP2007501775A (ja) | 2003-08-07 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤 |
| US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CN101010298A (zh) | 2004-04-05 | 2007-08-01 | 默克Hdac研究有限责任公司 | 组蛋白脱乙酰酶抑制剂前药 |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| ATE542527T1 (de) | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| WO2008067027A2 (en) | 2006-10-20 | 2008-06-05 | Icos Corporation | Compositions of chkl inhibitors and cyclodextrin |
| GB0621160D0 (en) | 2006-10-24 | 2006-12-06 | Imp College Innovations Ltd | Compounds and uses thereof |
| TWI519313B (zh) | 2006-11-20 | 2016-02-01 | 希佛隆公司 | 使用放射敏感劑放射敏感化腫瘤之方法 |
| CN101084876A (zh) | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| US20090131367A1 (en) | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| US8987468B2 (en) | 2008-02-04 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| CA2735899A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| MX2011003751A (es) | 2008-10-08 | 2011-04-27 | Cephalon Inc | Procesos para preparar bendamustina. |
| WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
| HRP20150778T1 (hr) | 2009-01-23 | 2015-08-28 | Euro-Celtique S.A. | Derivati hidroksamske kiseline |
| ES2525257T3 (es) | 2009-02-25 | 2014-12-19 | Supratek Pharma, Inc. | Composiciones de ciclopolisacárido y de bendamustina |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| WO2011017448A1 (en) | 2009-08-05 | 2011-02-10 | The Trustees Of The University Of Pennsylvania | Use of histone deacetylase inhibitors for treatment of autoimmune diseases |
| CN101928234B (zh) | 2010-01-15 | 2012-12-12 | 北京欧凯纳斯科技有限公司 | 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法 |
| WO2011130689A1 (en) | 2010-04-15 | 2011-10-20 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| US9889147B2 (en) | 2010-04-16 | 2018-02-13 | Cellact Pharma Gmbh | Analogues of etoposide for the treatment of tumours |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| US8748470B2 (en) | 2011-03-17 | 2014-06-10 | The University Of Chicago | Methods for treating ovarian cancer by inhibiting fatty acid binding proteins |
| JP6330118B2 (ja) | 2011-09-13 | 2018-05-30 | ファーマサイクリックス エルエルシー | ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用 |
| CN102993102B (zh) | 2011-09-16 | 2016-08-24 | 杭州民生药业有限公司 | [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法 |
| DK2758052T3 (en) | 2011-09-18 | 2018-05-28 | Euro Celtique Sa | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
| RS55680B1 (sr) | 2011-09-28 | 2017-07-31 | Euro Celtique Sa | Derivati azotnih iperita |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| EP3076963A4 (en) | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
| NZ630314A (en) | 2014-02-18 | 2016-03-31 | Celgene Corp | Combination therapy for hematological malignancies |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| CN106580971B (zh) | 2015-10-20 | 2019-11-12 | 杭州梯诺医药科技有限公司 | 一种药物组合物及其制备方法 |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| US20180098969A1 (en) | 2016-10-11 | 2018-04-12 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| KR20210105380A (ko) | 2018-12-18 | 2021-08-26 | 먼디파머 인터내셔널 코포레이션 리미티드 | 다발성 골수종을 치료하기 위한 화합물 |
-
2017
- 2017-06-13 GB GBGB1709402.0A patent/GB201709402D0/en not_active Ceased
-
2018
- 2018-06-13 AR ARP180101622A patent/AR112101A1/es unknown
- 2018-06-13 KR KR1020197037098A patent/KR102655833B1/ko active Active
- 2018-06-13 BR BR112019026484-1A patent/BR112019026484A2/pt not_active Application Discontinuation
- 2018-06-13 ES ES18733527T patent/ES2966954T3/es active Active
- 2018-06-13 TW TW107120389A patent/TW201919616A/zh unknown
- 2018-06-13 AU AU2018285821A patent/AU2018285821B2/en active Active
- 2018-06-13 CA CA3067276A patent/CA3067276A1/en active Pending
- 2018-06-13 JP JP2019568675A patent/JP7195283B2/ja active Active
- 2018-06-13 WO PCT/EP2018/065664 patent/WO2018229132A1/en not_active Ceased
- 2018-06-13 MX MX2019015208A patent/MX392103B/es unknown
- 2018-06-13 US US16/621,898 patent/US11318117B2/en active Active
- 2018-06-13 EP EP18733527.8A patent/EP3638231B1/en active Active
-
2019
- 2019-11-28 IL IL271017A patent/IL271017A/en unknown
-
2022
- 2022-04-27 US US17/730,276 patent/US11918558B2/en active Active
-
2024
- 2024-01-25 US US18/422,118 patent/US12370178B2/en active Active
-
2025
- 2025-07-28 US US19/282,336 patent/US20260083707A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2966954T3 (es) | 2024-04-25 |
| US11918558B2 (en) | 2024-03-05 |
| KR102655833B1 (ko) | 2024-04-08 |
| JP2020523359A (ja) | 2020-08-06 |
| JP7195283B2 (ja) | 2022-12-23 |
| TW201919616A (zh) | 2019-06-01 |
| US11318117B2 (en) | 2022-05-03 |
| BR112019026484A2 (pt) | 2020-07-14 |
| EP3638231B1 (en) | 2023-12-20 |
| US20220401417A1 (en) | 2022-12-22 |
| AR112101A1 (es) | 2019-09-18 |
| US12370178B2 (en) | 2025-07-29 |
| WO2018229132A1 (en) | 2018-12-20 |
| IL271017A (en) | 2020-01-30 |
| US20260083707A1 (en) | 2026-03-26 |
| US20200113871A1 (en) | 2020-04-16 |
| EP3638231A1 (en) | 2020-04-22 |
| EP3638231C0 (en) | 2023-12-20 |
| US20240316009A1 (en) | 2024-09-26 |
| AU2018285821B2 (en) | 2024-07-04 |
| GB201709402D0 (en) | 2017-07-26 |
| KR20200015563A (ko) | 2020-02-12 |
| MX2019015208A (es) | 2022-05-03 |
| CA3067276A1 (en) | 2018-12-20 |
| AU2018285821A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392103B (es) | Compuestos para el tratamiento de la t-pll. | |
| CY1121930T1 (el) | Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες | |
| EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
| MX2023005098A (es) | Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. | |
| EP3755234A4 (en) | LIGHTED MEDICAL DEVICES | |
| MX386547B (es) | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. | |
| MX2017009449A (es) | Inhibidor jak. | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| EA201692436A1 (ru) | Медицинское применение | |
| UY35834A (es) | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon | |
| UY36649A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX390945B (es) | Compuestos para el tratamiento de tnbc. | |
| MX388722B (es) | Compuestos para tratar el cancer de ovario. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
| MX2017005255A (es) | Derivados de carbazol. | |
| UY35359A (es) | 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO | |
| MX2016014859A (es) | Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas. | |
| CR20160527A (es) | Derivados de carboxamida | |
| MX394213B (es) | Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos. | |
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| EA201991141A1 (ru) | Усилители bmp |